• Ibrexafungerp in Translational Antifungal Models: Mechanisms

  2026-05-03

  Explore the unique translational and mechanistic insights of Ibrexafungerp (MK 3118), an oral triterpenoid antifungal, with a focus on advanced animal models and real-world resistance challenges. Discover evidence-driven protocol parameters and practical assay guidance distinct from prior reviews.

• PD 173074 (SKU A8253): Reliable FGFR/VEGFR2 Inhibition in Ce

  2026-05-02

  This scenario-driven guide equips biomedical researchers and lab technicians with validated strategies for using PD 173074 (SKU A8253) in cell viability, proliferation, and cytotoxicity assays. Integrating real laboratory challenges, recent literature, and vendor comparison, this article demonstrates how PD 173074’s nanomolar potency and selectivity deliver reproducible results in FGFR and VEGFR2 pathway research.

• Spleen-Targeted Neoantigen mRNA Vaccine Drives TLS in HCC

  2026-05-01

  Lin et al. introduce a spleen-targeted neoantigen mRNA vaccine (STNvac) that robustly induces ISG15+ CD8+ T cells, promoting tertiary lymphoid structure formation and significant antitumor activity in hepatocellular carcinoma. This study advances our understanding of organ-targeted mRNA vaccination and highlights new immune mechanisms relevant to solid tumor immunotherapy.

• Applied Use-Cases of Tivozanib (AV-951) in Oncology Research

  2026-05-01

  Tivozanib (AV-951) delivers best-in-class VEGFR inhibition with exceptional selectivity and potency, streamlining anti-angiogenic workflows in renal cell carcinoma and solid tumor models. This article translates cutting-edge in vitro findings and protocol optimizations into actionable guidance for maximizing Tivozanib’s impact in translational oncology.

• Merimepodib (VX-497): IMPDH Inhibition for Antiviral & Immun

  2026-04-30

  Merimepodib (VX-497) is a selective, orally bioavailable IMPDH inhibitor used in research as an antiviral, immunosuppressive, and cancer chemotherapy agent. Its mechanism—disrupting guanine nucleotide biosynthesis—enables precise control over cell proliferation and viral replication. APExBIO provides validated compound B1112 for advanced laboratory workflows.

• Ginsenoside Rg1: Applied Neuroprotection and Workflow Advanc

  2026-04-30

  Ginsenoside Rg1, a benchmark triterpene saponin, enables precise modeling of neuroimmune interactions and gut-brain axis restoration in advanced neuroprotection research. This article delivers actionable protocol insights, troubleshooting strategies, and the latest reference-backed workflow enhancements for apoptosis and inflammation studies.

• In Vitro Drug Response Metrics: Insights for Cancer Research

  2026-04-29

  Schwartz's dissertation redefines how in vitro cancer drug responses are quantified, distinguishing between relative and fractional viability to better capture the interplay of proliferative arrest and cell death. This nuanced approach offers improved assay design and interpretation, with implications for evaluating targeted agents such as tyrosine kinase inhibitors.

• Foretinib (GSK1363089): Optimizing Tumor Cell Assays in Canc

  2026-04-29

  Foretinib (GSK1363089) stands out as a robust ATP-competitive multikinase inhibitor for dissecting tumor growth, cell motility, and metastasis in translational cancer models. This guide consolidates evidence-based workflows, troubleshooting insights, and best practices to maximize reproducibility and impact in preclinical oncology research.

• Reelin Signaling as a Determinant of Ketamine Antidepressant

  2026-04-28

  This study demonstrates that intact synaptic Reelin signaling is essential for ketamine's antidepressant and synaptic effects in the hippocampus. Disruption of the Reelin-Apoer2-SFK pathway impairs both behavioral and neurophysiological responses to ketamine, providing mechanistic insight into nonresponsiveness in treatment-resistant depression.

• Red Blood Cell Lysis Buffer: Mechanistic Insights for Transl

  2026-04-28

  Unlock the full potential of blood sample preparation with evidence-driven guidance on ammonium chloride-based erythrocyte lysis. This article bridges mechanistic understanding with strategic workflow integration, enabling translational researchers to achieve reproducible, high-quality results in hematology and immunology. We position APExBIO’s Red Blood Cell Lysis Buffer as the gold standard, drawing from recent molecular research and comparative analyses.

• Precision Use of Pazopanib (GW-786034) in Advanced Cancer Mo

  2026-04-27

  Explore how Pazopanib (GW-786034) redefines precision cancer research through advanced mechanistic insights, context-driven protocol optimization, and data-backed application in ATRX-deficient tumor models. This article uniquely bridges molecular pharmacology with practical assay decisions.

• Sunitinib: Multi-Targeted RTK Inhibitor in Renal Cell Carcin

  2026-04-27

  Sunitinib empowers cancer researchers with precise, multi-pathway RTK inhibition and robust anti-angiogenic effects, now further enhanced by innovative combination strategies. Explore actionable workflows, protocol optimizations, and cutting-edge applications in renal cell carcinoma and beyond.

• Salinomycin as a Polyether Ionophore: Mechanistic Insights f

  2026-04-26

  Explore the mechanistic depth of Salinomycin, a polyether ionophore antibiotic, in hepatocellular carcinoma research. This article uniquely integrates molecular transport mechanisms, cytotoxicity considerations, and advanced protocol guidance for maximizing experimental rigor.

• Resiniferatoxin (RTX): Transforming Analgesia Research in OA

  2026-04-25

  Resiniferatoxin (RTX) stands out as a selective and ultra-potent TRPV1 agonist, delivering unprecedented nerve desensitization and durable pain relief in preclinical and clinical models of osteoarthritis. With precise dosing and robust safety profiles, RTX unlocks advanced workflows for dissecting pain pathways and developing next-generation analgesic agents.

• BH3 Mimetics Target Senescent Cells in TP53 Wild-Type Breast

  2026-04-24

  This study demonstrates that BH3 mimetics, specifically BCL-XL inhibitors, selectively eliminate chemotherapy-induced senescent breast cancer cells in TP53 wild-type settings. The findings highlight a strategy to minimize residual disease and improve outcomes in patient populations that typically show poor chemotherapy responses.

15475 records 1/1032 page Next 12345 下5页 Last page